Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022PRNewsWire • 03/03/22
Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San AntonioPRNewsWire • 02/15/22
Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of CancerBenzinga • 01/24/22
Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous SystemPRNewsWire • 01/24/22
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid TumorsPRNewsWire • 01/18/22
Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284PRNewsWire • 01/12/22
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/14/21
Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer DayPRNewsWire • 11/12/21
Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual MeetingPRNewsWire • 11/11/21
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual MeetingPRNewsWire • 11/04/21
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/02/21
Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating HighlightsPRNewsWire • 11/01/21
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potential for Biopharma Collaborations and PartnershipsPRNewsWire • 11/01/21
Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development CollaborationsPRNewsWire • 10/27/21
Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug DevelopmentPRNewsWire • 10/27/21
Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ETPRNewsWire • 10/25/21
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021Accesswire • 09/30/21
Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung CancerPRNewsWire • 09/28/21
Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During SeptemberPRNewsWire • 09/07/21
Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing InitiativesPRNewsWire • 09/02/21
FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant GliomasPRNewsWire • 08/30/21
